As chemo overtreatment comes into focus, Atossa bets on tamoxifen’s active form 

Summary

Atossa Therapeutics is developing endoxifen, the active metabolite of tamoxifen, as a potential treatment for hormone receptor-positive, HER2-negative breast cancer patients who may be overexposed to chemotherapy. The company aims to expand treatment options for patients who can safely avoid chemotherapy.